RxDoctor Payments Data

Khalid Mumtaz, MD

Gastroenterology · Columbus, OHNPI 1265831689

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,060 of the $9,427 with a category attached, or 85.5%. Mallinckrodt Hospital Products Inc. accounts for 95.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $9,163 and has fallen 98.5% since, to $136 in 2024.

$9,427in general payments, 2019–2025

Across 10 payments — averaging $942.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$9K
  • Intercept Pharmaceuticals, Inc.$248
  • Madrigal Pharmaceuticals$136
$248,721in research payments, 2019–2025

Across 104 payments — averaging $2391.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$148K
  • Bausch Health US, LLC$87K
  • Intercept Pharmaceuticals, Inc.$6K
  • Grifols Therapeutics LLC$5K
  • Mallinckrodt Hospital Products Inc.$2K

What the payments were for

  • Speaking & faculty fees$8,06086%
  • Travel & lodging$7638%
  • Food & beverage$6046%

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,427 in reported general payments places this provider in the 75th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$68,676
Medicare patients
334
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin97$302,253
Everolimus49$134,605
Tacrolimus276$36,563
LokelmaSodium Zirconium Cyclosilicate44$33,159
VemlidyTenofovir Alafenamide23$30,845
Mycophenolic AcidMycophenolate Sodium95$29,061
Envarsus XrTacrolimus13$22,547
Ursodiol118$14,895
Entecavir46$6,238
Mycophenolate Mofetil89$4,319
Budesonide DrBudesonide17$3,498
Cyclosporine ModifiedCyclosporine, Modified27$3,222
Lactulose88$2,990
Spironolactone179$1,619
Nadolol46$1,339

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →